Brandon M Nathan1, Maria J Redondo2, Heba Ismail3, Laura Jacobsen4, Emily K Sims3, Jerry Palmer5, Jay Skyler6, Laura Bocchino7, Susan Geyer7,8, Jay M Sosenko6. 1. University of Minnesota, Minneapolis, MN. 2. Baylor College of Medicine, Texas Children's Hospital, Houston, TX. 3. Indiana University School of Medicine, Indianapolis, IN. 4. University of Florida, Gainesville, FL. 5. University of Washington, Seattle, WA. 6. University of Miami, Miami, FL. 7. University of South Florida, Tampa, FL. 8. Mayo Clinic, Rochester, MN.
Abstract
OBJECTIVE: We assessed whether Index60, a composite measure of fasting C-peptide, 60-min C-peptide, and 60-min glucose, could improve the metabolic staging of type 1 diabetes for progression to clinical disease (stage 3) among autoantibody-positive (Ab+) individuals with normal 2-h glucose values (<140 mg/dL). RESEARCH DESIGN AND METHODS: We analyzed 3,058 Type 1 Diabetes TrialNet Pathway to Prevention participants with 2-h glucose <140 mg/dL and Index60 <1.00 values from baseline oral glucose tolerance tests. Characteristics associated with type 1 diabetes (younger age, greater Ab+, higher HLA DR3-DQ2/DR4-DQ8 prevalence, and lower C-peptide) were compared among four mutually exclusive groups: top 2-h glucose quartile only (HI-2HGLU), top Index60 quartile only (HI-IND60), both top quartiles (HI-BOTH), and neither top quartile (LO-BOTH). Additionally, within the 2-h glucose distribution of <140 mg/dL and separately within the Index60 <1.00 distribution, comparisons were made between those above or below the medians. RESULTS: HI-IND60 and HI-BOTH were younger, with greater frequency of more than two Ab+, and lower C-peptide levels, than either HI-2HGLU or LO-BOTH (all P < 0.001). The cumulative incidence for stage 3 was greater for HI-IND60 and HI-BOTH than for either HI-2HGLU or LO-BOTH (all P < 0.001). Those with Index60 values above the median were younger and had higher frequency of two or more Ab+ (P < 0.001) and DR3-DQ2/DR4-DQ8 prevalence (P < 0.001) and lower area under the curve (AUC) C-peptide levels (P < 0.001) than those below. Those above the 2-h glucose median had higher AUC C-peptide levels (P < 0.001), but otherwise did not differ from those below. CONCLUSIONS: Index60 identifies individuals with characteristics of type 1 diabetes at appreciable risk for progression who would otherwise be missed by 2-h glucose staging criteria.
OBJECTIVE: We assessed whether Index60, a composite measure of fasting C-peptide, 60-min C-peptide, and 60-min glucose, could improve the metabolic staging of type 1 diabetes for progression to clinical disease (stage 3) among autoantibody-positive (Ab+) individuals with normal 2-h glucose values (<140 mg/dL). RESEARCH DESIGN AND METHODS: We analyzed 3,058 Type 1 Diabetes TrialNet Pathway to Prevention participants with 2-h glucose <140 mg/dL and Index60 <1.00 values from baseline oral glucose tolerance tests. Characteristics associated with type 1 diabetes (younger age, greater Ab+, higher HLA DR3-DQ2/DR4-DQ8 prevalence, and lower C-peptide) were compared among four mutually exclusive groups: top 2-h glucose quartile only (HI-2HGLU), top Index60 quartile only (HI-IND60), both top quartiles (HI-BOTH), and neither top quartile (LO-BOTH). Additionally, within the 2-h glucose distribution of <140 mg/dL and separately within the Index60 <1.00 distribution, comparisons were made between those above or below the medians. RESULTS: HI-IND60 and HI-BOTH were younger, with greater frequency of more than two Ab+, and lower C-peptide levels, than either HI-2HGLU or LO-BOTH (all P < 0.001). The cumulative incidence for stage 3 was greater for HI-IND60 and HI-BOTH than for either HI-2HGLU or LO-BOTH (all P < 0.001). Those with Index60 values above the median were younger and had higher frequency of two or more Ab+ (P < 0.001) and DR3-DQ2/DR4-DQ8 prevalence (P < 0.001) and lower area under the curve (AUC) C-peptide levels (P < 0.001) than those below. Those above the 2-h glucose median had higher AUC C-peptide levels (P < 0.001), but otherwise did not differ from those below. CONCLUSIONS: Index60 identifies individuals with characteristics of type 1 diabetes at appreciable risk for progression who would otherwise be missed by 2-h glucose staging criteria.
Authors: David M Maahs; Nancy A West; Jean M Lawrence; Elizabeth J Mayer-Davis Journal: Endocrinol Metab Clin North Am Date: 2010-09 Impact factor: 4.741
Authors: G Blohmé; L Nyström; H J Arnqvist; F Lithner; B Littorin; P O Olsson; B Scherstén; L Wibell; J Ostman Journal: Diabetologia Date: 1992-01 Impact factor: 10.122
Authors: J Ostman; G Lönnberg; H J Arnqvist; G Blohmé; J Bolinder; A Ekbom Schnell; J W Eriksson; S Gudbjörnsdottir; G Sundkvist; L Nyström Journal: J Intern Med Date: 2008-01-16 Impact factor: 8.989
Authors: Carmella Evans-Molina; Emily K Sims; Linda A DiMeglio; Heba M Ismail; Andrea K Steck; Jerry P Palmer; Jeffrey P Krischer; Susan Geyer; Ping Xu; Jay M Sosenko Journal: JCI Insight Date: 2018-08-09
Authors: Alberto Pugliese; David Boulware; Liping Yu; Sunanda Babu; Andrea K Steck; Dorothy Becker; Henry Rodriguez; Linda DiMeglio; Carmella Evans-Molina; Leonard C Harrison; Desmond Schatz; Jerry P Palmer; Carla Greenbaum; George S Eisenbarth; Jay M Sosenko Journal: Diabetes Date: 2016-01-28 Impact factor: 9.461
Authors: Anette G Ziegler; Marian Rewers; Olli Simell; Tuula Simell; Johanna Lempainen; Andrea Steck; Christiane Winkler; Jorma Ilonen; Riitta Veijola; Mikael Knip; Ezio Bonifacio; George S Eisenbarth Journal: JAMA Date: 2013-06-19 Impact factor: 56.272
Authors: Janelle A Noble; Ana Maria Valdes; Michael D Varney; Joyce A Carlson; Priscilla Moonsamy; Anna Lisa Fear; Julie A Lane; Eva Lavant; Rebecca Rappner; Anthony Louey; Patrick Concannon; Josyf C Mychaleckyj; Henry A Erlich Journal: Diabetes Date: 2010-08-26 Impact factor: 9.461
Authors: Jay M Sosenko; Jerry P Palmer; Lisa E Rafkin; Jeffrey P Krischer; David Cuthbertson; Carla J Greenbaum; George Eisenbarth; Jay S Skyler Journal: Diabetes Care Date: 2009-12-23 Impact factor: 17.152
Authors: Jay M Sosenko; Jay S Skyler; Jeffrey Mahon; Jeffrey P Krischer; Carla J Greenbaum; Lisa E Rafkin; Craig A Beam; David C Boulware; Della Matheson; David Cuthbertson; Kevan C Herold; George Eisenbarth; Jerry P Palmer Journal: Diabetes Care Date: 2014-02-18 Impact factor: 19.112
Authors: Laura M Jacobsen; Brian N Bundy; Heba M Ismail; Mark Clements; Megan Warnock; Susan Geyer; Desmond A Schatz; Jay M Sosenko Journal: J Clin Endocrinol Metab Date: 2022-09-28 Impact factor: 6.134